

## AMENDMENT

### In the Claims

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-40 (Canceled)

41. (Currently amended) A fusion protein comprising ~~the~~ an immunogenic polypeptide, wherein the immunogenic polypeptide consists of the amino acid sequence motif  
Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-  
Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8) of claim 53.

42. (Currently amended) The immunogenic polypeptide of claim 53 41 linked to a suitable carrier.

43. (Previously presented) The immunogenic polypeptide of claim 42 linked to a disulfide/amide-forming agent.

44. (Previously presented) The immunogenic polypeptide of claim 42 linked to a thio-ether-forming agent.

45-51. (Canceled)

52. (Currently amended) An immunogenic composition comprising a pharmaceutically acceptable carrier and the immunogenic polypeptide of claim 53 41.

53. (Cancelled)

54. (Canceled)

55. (Previously presented) The immunogenic polypeptide of claim 42, wherein the carrier is diphtheria toxoid.

56. (Previously presented) The immunogenic composition of claim 52, wherein the carrier is diphtheria toxoid.

57. (Canceled)